lopinavir has been researched along with Liver Dysfunction in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, J; Cheng, X; Fan, Z; Huang, S; Li, J; Liu, Z; Tian, C; Yang, J; Zhang, Y | 1 |
| Bernasconi, E; Bertoli, R; Cerny, A; Ceschi, A; De Gottardi, A; Fratila, C; Gianella, P; Magenta, L; Majno-Hurst, P; Vanini, G | 1 |
| Chen, H; Deng, C; Du, Q; Guo, Y; Huang, X; Li, T; Lu, S; Yue, R | 1 |
| Chen, K; Chen, X; Chen, Y; Cheng, J; Guan, X; Huang, R; Huang, S; Ji, F; Li, C; Liu, J; Liu, L; Ming, F; Sang, D; Shao, H; Wang, J; Wu, C; Xu, T; Xue, L; Yan, X; Zhang, B; Zhao, H; Zhao, XA; Zhao, Y; Zhu, C; Zhu, L | 1 |
| Ravi, PR; Vats, R | 1 |
| Arya, V; Au, S; Mullick, C; Struble, K; Wagner, C; Zhao, P | 1 |
| Heinz, W; Hubert, C; Klinker, H; Langmann, P; Leyh, M; Schnaitmann, E; Trein, A; Winzer, R | 1 |
| Eghtesad, B; Fung, JJ; Jain, AB; Marcos, A; Rafail, AB; Ragni, M; Shapiro, R; Venkataramanan, R | 1 |
| Bini, T; Bonfanti, P; Cristina, G; Miccolis, S; Orofino, G; Penco, G; Quirino, T; Ricci, E; Sfara, C | 1 |
| Arribas, J; Brun, SC; Causemaker, SJ; Cepeda, C; DaSilva, B; García Cabanillas, JA; Li, J; Lorenzo, A; Peng, JZ; Pulido, F | 1 |
| Battegay, M; Blick, G; Kraft, M; Neubacher, D; Opravil, M; Raffi, F; Rusconi, S; Sabo, JP; Steigbigel, RT | 1 |
1 trial(s) available for lopinavir and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Topics: Adult; Area Under Curve; Biological Availability; Drug Combinations; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Pyrimidinones; Radioligand Assay; Ritonavir | 2006 |
10 other study(ies) available for lopinavir and Liver Dysfunction
| Article | Year |
|---|---|
Clinical Features of COVID-19-Related Liver Functional Abnormality.
Topics: Adult; Antiviral Agents; Betacoronavirus; Bilirubin; Blood Chemical Analysis; China; Coronavirus Infections; COVID-19; Enzymes; Female; Hospitals; Humans; Liver Diseases; Liver Function Tests; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prevalence; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
Topics: Antiviral Agents; Comorbidity; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunosuppression Therapy; Liver Diseases; Liver Transplantation; Lopinavir; Lung; Male; Meropenem; Middle Aged; Ritonavir; SARS-CoV-2 | 2020 |
[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].
Topics: Aged; Aged, 80 and over; Antiviral Agents; China; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Severity of Illness Index; Treatment Outcome | 2020 |
Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: A retrospective, multi-center study.
Topics: Adult; China; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Liver Diseases; Liver Function Tests; Lopinavir; Male; Middle Aged; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2; Viral Protease Inhibitors | 2021 |
Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Area Under Curve; Disease Models, Animal; Lipids; Liver Diseases; Lopinavir; Male; Nanoparticles; Rats; Rats, Wistar; Tissue Distribution | 2017 |
Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.
Topics: Adult; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Drug Interactions; Female; Healthy Volunteers; HIV Protease Inhibitors; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Models, Biological; Ritonavir; Young Adult | 2017 |
Safety of long-term lopinavir plasma-levels in patients with liver disease.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Chronic Disease; Drug Monitoring; Female; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies | 2008 |
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.
Topics: Adult; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Diseases; Liver Transplantation; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Tacrolimus | 2003 |
Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Italy; Liver Diseases; Lopinavir; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrimidinones; Ritonavir | 2005 |
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
Topics: Alanine Transaminase; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Lopinavir; Peptide Fragments; Pyridines; Pyrimidinones; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome; Viral Load | 2007 |